Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2016 | Editorial Commentary

Evaluation of ¹²⁴I PET/CT and ¹²⁴I PET/MRI in the management of patients with differentiated thyroid cancer

Authors: Laurent Dercle, Désirée Deandreis, Marie Terroir, Sophie Leboulleux, Jean Lumbroso, Martin Schlumberger

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2016

Excerpt

In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, Binse and colleagues report the results of ¹²⁴I PET/MRI in comparison with those of ¹²⁴I PET/CT in patients with differentiated thyroid cancer (DTC). The two separate PET acquisitions explored the neck, 24 h after ¹²⁴I intake. This elegant study showed the superiority of the PET component associated with the MRI device over the PET component associated with the CT device as it detected more iodine-positive metastases (72 vs. 60 tumour lesions, p = 0.002) and identified additional patients with at least one tumour lesion (21/65 vs. 17/65 patients, p = n.s.) using a 2-min acquisition time. The assumed explanation was better lesion-to-background contrast due to an improved PET device (better geometry of the detector systems and sensitive area of the crystals), which allowed better detection of thyroid tumour foci, taking advantage of their unique prolonged ¹²⁴I accumulation. In fact, two acquisitions were performed with PET/MRI: a 30-minute PET acquisition covered the neck MRI acquisition time and increased the detection rate of tumour lesions by 22 % in comparison with the previously cited 2-min PET acquisition (88 vs. 72, p = 0.07). The conclusion of this study was that ¹²⁴I PET/MRI shows no substantial advantage over ¹²⁴I PET/CT for the detection of tumour lesions in the neck when using similar PET devices and that the MRI component does not significantly improve sensitivity or specificity in the detection of neck lesions as compared to the CT component. …

Stahl AR, Freudenberg L, Bockisch A, Jentzen W. A novel view on dosimetry-related radionuclide therapy: presentation of a calculatory model and its implementation for radioiodine therapy of metastasized differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1147–55. doi:10.1007/s00259-009-1077-1.CrossRefPubMed

Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46 Suppl 1:28S–37S.PubMed

Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–41. doi:10.1056/NEJM198310203091601.CrossRefPubMed

Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7:183–7.CrossRefPubMed

Maxon 3rd HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer – a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33:1132–6.PubMed

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73. doi:10.1056/NEJMoa1108586.CrossRefPubMed

Borget I, Bonastre J, Catargi B, Deandreis D, Zerdoud S, Rusu D, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol. 2015;33:2885–92. doi:10.1200/JCO.2015.61.6722.CrossRefPubMed

Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759–65. doi:10.2967/jnumed.114.144089.CrossRefPubMed

Erdi YE, Macapinlac H, Larson SM, Erdi AK, Yeung H, Furhang EE, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging. 1999;2:41–6.CrossRefPubMed

10.

Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017–23. doi:10.2967/jnumed.107.047159.CrossRefPubMed

11.

Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–72.PubMed

12.

Freudenberg LS, Jentzen W, Gorges R, Petrich T, Marlowe RJ, Knust J, et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46:121–8.PubMed

13.

Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760–7. doi:10.1007/s00259-002-0775-8.CrossRefPubMed

14.

Jentzen W, Freudenberg L, Bockisch A. Quantitative imaging of (124)I with PET/CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. Q J Nucl Med Mol Imaging. 2011;55:21–43.PubMed

15.

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9. doi:10.1210/jc.2005-2838.CrossRefPubMed

16.

Martinez-Moller A, Souvatzoglou M, Delso G, Bundschuh RA, Chefd’hotel C, Ziegler SI, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520–6. doi:10.2967/jnumed.108.054726.CrossRefPubMed

17.

Jeong JH, Cho IH, Kong EJ, Chun KA. Evaluation of Dixon sequence on hybrid PET/MR compared with contrast-enhanced PET/CT for PET-positive lesions. Nucl Med Mol Imaging. 2014;48:26–32. doi:10.1007/s13139-013-0240-6.CrossRefPubMedPubMedCentral

18.

Nagarajah J, Jentzen W, Hartung V, Rosenbaum-Krumme S, Mikat C, Heusner TA, et al. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. Eur J Nucl Med Mol Imaging. 2011;38:1862–8. doi:10.1007/s00259-011-1866-1.CrossRefPubMed

19.

Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879–83. doi:10.1089/thy.2009.0430.CrossRefPubMed

20.

Freudenberg LS, Jentzen W, Muller SP, Bockisch A. Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging. 2008;35:502–8. doi:10.1007/s00259-007-0601-4.CrossRefPubMed

21.

Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:958–65. doi:10.1007/s00259-007-0660-6.CrossRefPubMedPubMedCentral

22.

de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT/CT. Eur J Nucl Med Mol Imaging. 2013;40:693–700. doi:10.1007/s00259-012-2331-5.CrossRefPubMed

23.

Haugen BR, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi:10.1089/thy.2015.0020.CrossRefPubMed

24.

Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 2012;39:1373–80. doi:10.1007/s00259-012-2065-4.CrossRefPubMed

25.

Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab. 2007;3:112–21. doi:10.1038/ncpendmet0402.CrossRefPubMed

26.

Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kuhl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:950–7. doi:10.1007/s00259-007-0634-8.CrossRefPubMed

27.

Leboulleux S, El Bez I, Borget I, Elleuch M, Deandreis D, Al Ghuzlan A, et al. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012;22:832–8. doi:10.1089/thy.2012.0081.CrossRefPubMed

28.

Chen Q, Raghavan P, Mukherjee S, Jameson MJ, Patrie J, Xin W, et al. Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer. Radiol Med. 2015;120:959–66. doi:10.1007/s11547-014-0474-0.CrossRefPubMed

29.

Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11. doi:10.1089/thy.2007.0135.CrossRefPubMed

30.

Vrachimis A, Burg MC, Wenning C, Allkemper T, Weckesser M, Schafers M, et al. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:212–20. doi:10.1007/s00259-015-3195-2.CrossRefPubMed

31.

Sakurai Y, Kawai H, Iwano S, Ito S, Ogawa H, Naganawa S. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. J Med Imaging Radiat Oncol. 2013;57:297–305. doi:10.1111/1754-9485.12020.CrossRefPubMed

32.

Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48–56. doi:10.1007/s00259-011-1773-5.CrossRefPubMed

Title: Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer
Authors: Laurent Dercle
Désirée Deandreis
Marie Terroir
Sophie Leboulleux
Jean Lumbroso
Martin Schlumberger
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3334-4

At a glance: The STEP trials

Springer Medicine

Evaluation of ¹²⁴I PET/CT and ¹²⁴I PET/MRI in the management of patients with differentiated thyroid cancer

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2016

Molecular imaging with 99mTc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison

18F-DOPA: the versatile radiopharmaceutical

Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas

Imaging of differentiated thyroid carcinoma: 124I-PET/MRI may not be superior to 124I-PET/CT

The Pathophysiologic Basis of Nuclear Medicine, Third Edition, Abdelhamid H. Elgazzar, Ed.

Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study